UNSPSC 51294205: Oxaflozane

This classification denotes an antidepressant agent with the molecular formula C14H18F3NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V4WLW77V5Q, chemically known as 4-isopropyl-2-(alpha,alpha,alpha-trifluoro-m-tolyl)morpholine but generally known as oxaflozane, which bears US NIH Compound Identifier 71915. European Medicines Agency schedules Oxaflozane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09486MIG.

UNSPSC 51294205 Oxaflozane is a Commodity code that in current state and local procurement activity spans pharmaceutical products far broader than the code's specific drug name alone—including naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. State and local issuers under this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of participating state and local facilities across Oregon and Minnesota). The work being solicited ranges from direct procurement of specific pharmaceutical units for community health initiatives to formal RFPs establishing statewide or multi-state contracts for generic pharmaceuticals distributed through authorized drug wholesalers, and exploratory RFIs seeking vendor capabilities for direct-to-manufacturer prescription programs that bypass traditional pharmacy benefit managers.

Recent activity concentrates in Texas, Florida, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with responses due July 26, 2023. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026 and contract effectiveness July 1, 2026; vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson Co., LLC) and comply with cGMP and Drug Supply Chain Security Act certification. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, as an exploratory solicitation gathering vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to inform future formal procurement strategy.